Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Anthony William James Cooper is active.

Publication


Featured researches published by Anthony William James Cooper.


Journal of Chemical Information and Modeling | 2010

Lead Optimization Using Matched Molecular Pairs: Inclusion of Contextual Information for Enhanced Prediction of hERG Inhibition, Solubility, and Lipophilicity

George Papadatos; Muhammad Alkarouri; Valerie J. Gillet; Peter Willett; Visakan Kadirkamanathan; Christopher N. Luscombe; Gianpaolo Bravi; Nicola J. Richmond; Stephen D. Pickett; Jameed Hussain; John M. Pritchard; Anthony William James Cooper; Simon J. F. Macdonald

Previous studies of the analysis of molecular matched pairs (MMPs) have often assumed that the effect of a substructural transformation on a molecular property is independent of the context (i.e., the local structural environment in which that transformation occurs). Experiments with large sets of hERG, solubility, and lipophilicity data demonstrate that the inclusion of contextual information can enhance the predictive power of MMP analyses, with significant trends (both positive and negative) being identified that are not apparent when using conventional, context-independent approaches.


Bioorganic & Medicinal Chemistry Letters | 2008

Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors.

J. Nicole Hamblin; Tony D. Angell; Stuart P. Ballantine; Caroline Mary Cook; Anthony William James Cooper; John Dawson; Christopher J. Delves; Paul Jones; Mika Kristian Lindvall; Fiona S. Lucas; Charlotte Jane Mitchell; Margarete Neu; Lisa E. Ranshaw; Yemisi E. Solanke; Don O. Somers; Joanne Wiseman

Optimisation of a high-throughput screening hit resulted in the discovery of 4-(substituted amino)-1-alkyl-pyrazolo[3,4-b]pyridine-5-carboxamides as potent and selective inhibitors of Phosphodiesterase 4 (PDE4). Herein, we describe early SAR studies around this novel template highlighting preferred substituents and rationalization of SAR through X-ray crystal structures of analogues bound to the PDE4 active site. Pyrazolopyridine 20a was found to be a potent and selective PDE4 inhibitor which also inhibits LPS induced TNF-alpha production from isolated human peripheral blood mononuclear cells and has an encouraging rat PK profile suitable for oral dosing.


Journal of Medicinal Chemistry | 2013

Optimized chemical probes for REV-ERBα

Ryan P. Trump; Stefano Bresciani; Anthony William James Cooper; James P. Tellam; Justyna Wojno; John Blaikley; Lisa A. Orband-Miller; Jennifer A. Kashatus; Mohamed Boudjelal; Helen C. Dawson; Andrew Loudon; David Ray; Daniel Grant; Stuart N. Farrow; Timothy M. Willson; Nicholas C. O. Tomkinson

REV-ERBα has emerged as an important target for regulation of circadian rhythm and its associated physiology. Herein, we report on the optimization of a series of REV-ERBα agonists based on GSK4112 (1) for potency, selectivity, and bioavailability. (1) Potent REV-ERBα agonists 4, 10, 16, and 23 are detailed for their ability to suppress BMAL and IL-6 expression from human cells while also demonstrating excellent selectivity over LXRα. Amine 4 demonstrated in vivo bioavailability after either iv or oral dosing.


Bioorganic & Medicinal Chemistry Letters | 1994

GR159897 and related analogues as highly potent, orally active non-peptide neurokinin NK2 receptor antagonists.

Anthony William James Cooper; Hilary S. Adams; Richard Bell; Paul Martin Gore; Andrew B. McElroy; John M. Pritchard; Paul W. Smith; Peter Ward

Abstract Optimisation of NK 2 receptor affinity in a series of sulfur derivatives resulted in the identification of Highly potent 5-fluoroindol-3-ylethyl[4-(phenylsulfinyl methyl])piperidines. Further structure activity analysis led to GR 159897 an NK 2 receptor antagonist which potently blocks agonist-induced bronchoconstriction in the guinea-pig when administered by peripheral and oral routes.


Journal of Chemical Information and Modeling | 2009

Analysis of neighborhood behavior in lead optimization and array design

George Papadatos; Anthony William James Cooper; Visakan Kadirkamanathan; Simon J. F. Macdonald; Iain M. McLay; Stephen D. Pickett; John M. Pritchard; Peter Willett; Valerie J. Gillet

Neighborhood behavior describes the extent to which small structural changes defined by a molecular descriptor are likely to lead to small property changes. This study evaluates two methods for the quantification of neighborhood behavior: the optimal diagonal method of Patterson et al. and the optimality criterion method of Horvath and Jeandenans. The methods are evaluated using twelve different types of fingerprint (both 2D and 3D) with screening data derived from several lead optimization projects at GlaxoSmithKline. The principal focus of the work is the design of chemical arrays during lead optimization, and the study hence considers not only biological activity but also important drug properties such as metabolic stability, permeability, and lipophilicity. Evidence is provided to suggest that the optimality criterion method may provide a better quantitative description of neighborhood behavior than the optimal diagonal method.


ACS Combinatorial Science | 2011

Synthesis of arrays using low molecular weight MPEG-assisted Mitsunobu reaction.

Marek Figlus; Natalie Wellaway; Anthony William James Cooper; Steven L. Sollis; Richard C. Hartley

Triphenylphosphine tagged with a short poly-(ethyleneglycol)-ω-monomethyl ether chain (light MPEG, 10−16 ethylenoxy units, (M)TPP-G2) and an MPEG-tagged version of diethyl azodicarboxylate ((M)DEAD) have been used to prepare a 20 member library of esters, ethers, and sulfonamides, with cLogPs in the range of 1.4−5.7 on a 0.1 mmol scale. Removal of MPEG-tagged side products was achieved by MPEG-assisted solid-phase extraction (MSPE) on prepacked silica columns to give the products in good yield and high purity.


Journal of Medicinal Chemistry | 2016

Evolution of a Novel, Orally Bioavailable Series of PI3Kδ Inhibitors from an Inhaled Lead for the Treatment of Respiratory Disease

Augustin Amour; Nicholas Paul Barton; Anthony William James Cooper; Graham G. A. Inglis; Craig Jamieson; Christopher N. Luscombe; Josie Morrell; Simon Peace; David Perez; Paul Rowland; Christopher John Tame; Sorif Uddin; Giovanni Vitulli; Natalie Wellaway

A four-step process of high-quality modeling of existing data, deconstruction, identification of replacement cores, and an innovative synthetic regrowth strategy led to the rapid discovery of a novel oral series of PI3Kδ inhibitors with promising selectivity and excellent in vivo characteristics.


Drug Discovery Today | 2013

A practical drug discovery project at the undergraduate level.

M. Jonathan Fray; Simon J. F. Macdonald; Ian Robert Baldwin; Nicholas Paul Barton; Jack A. Brown; Ian B. Campbell; Ian Churcher; Diane Mary Coe; Anthony William James Cooper; Andrew P. Craven; Gail Fisher; Graham G. A. Inglis; Henry A. Kelly; John Liddle; Aoife C. Maxwell; Vipulkumar Kantibhai Patel; Stephen Swanson; Natalie Wellaway

In this article, we describe a practical drug discovery project for third-year undergraduates. No previous knowledge of medicinal chemistry is assumed. Initial lecture workshops cover the basic principles; then students, in teams, seek to improve the profile of a weakly potent, insoluble phosphatidylinositide 3-kinase delta (PI3Kδ) inhibitor (1) through compound array design, molecular modelling, screening data analysis and the synthesis of target compounds in the laboratory. The project benefits from significant industrial support, including lectures, student mentoring and consumables. The aim is to make the learning experience as close as possible to real-life industrial situations. In total, 48 target compounds were prepared, the best of which (5b, 5j, 6b and 6ap) improved the potency and aqueous solubility of the lead compound (1) by 100-1000 fold and ≥tenfold, respectively.


Journal of Clinical Investigation | 2018

Circadian clock component REV-ERBα controls homeostatic regulation of pulmonary inflammation

Marie Pariollaud; Julie Gibbs; Thomas W. Hopwood; Sheila Brown; Nicola Begley; Ryan Vonslow; Toryn M. Poolman; Baoqiang Guo; Ben Saer; D. Heulyn Jones; James P. Tellam; Stefano Bresciani; Nicholas C. O. Tomkinson; Justyna Wojno-Picon; Anthony William James Cooper; Dion A. Daniels; Ryan P. Trump; Daniel Grant; William J. Zuercher; Timothy M. Willson; Andrew S. MacDonald; Brian Bolognese; Patricia L. Podolin; Yolanda Sanchez; Andrew Loudon; David Ray

Recent studies reveal that airway epithelial cells are critical pulmonary circadian pacemaker cells, mediating rhythmic inflammatory responses. Using mouse models, we now identify the rhythmic circadian repressor REV-ERB&agr; as essential to the mechanism coupling the pulmonary clock to innate immunity, involving both myeloid and bronchial epithelial cells in temporal gating and determining amplitude of response to inhaled endotoxin. Dual mutation of REV-ERB&agr; and its paralog REV-ERB&bgr; in bronchial epithelia further augmented inflammatory responses and chemokine activation, but also initiated a basal inflammatory state, revealing a critical homeostatic role for REV-ERB proteins in the suppression of the endogenous proinflammatory mechanism in unchallenged cells. However, REV-ERB&agr; plays the dominant role, as deletion of REV-ERB&bgr; alone had no impact on inflammatory responses. In turn, inflammatory challenges cause striking changes in stability and degradation of REV-ERB&agr; protein, driven by SUMOylation and ubiquitination. We developed a novel selective oxazole-based inverse agonist of REV-ERB, which protects REV-ERB&agr; protein from degradation, and used this to reveal how proinflammatory cytokines trigger rapid degradation of REV-ERB&agr; in the elaboration of an inflammatory response. Thus, dynamic changes in stability of REV-ERB&agr; protein couple the core clock to innate immunity.


Organic and Biomolecular Chemistry | 2016

Synthesis of dibenzylamino-1-methylcyclohexanol and dibenzylamino-1-trifluoromethylcyclohexanol isomers

D. Heulyn Jones; Stefano Bresciani; James P. Tellam; Justyna Wojno; Anthony William James Cooper; Alan R. Kennedy; Nicholas C. O. Tomkinson

The isomers of dibenzylamino-1-methylcyclohexan-1-ol and dibenzylamino-1-trifluoromethylcyclohexan-1-ol have been prepared. The stereochemistry of these compounds was unequivocally assigned through a combination of NMR spectroscopy and single crystal X-ray analysis. The cis-isomer of 3-N,N-dibenzylamino-1-trifluoromethylcyclohexanol and its derivatives display an unusual conformational behaviour in both solution-phase and the solid-state, where the amino group usually adopts an axial conformation.

Collaboration


Dive into the Anthony William James Cooper's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge